ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.
| Revenue (Most Recent Fiscal Year) | $20.46M |
| Net Income (Most Recent Fiscal Year) | $-30.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -159.94% |
| Net Margin (Trailing 12 Months) | -158.84% |
| Return on Equity (Trailing 12 Months) | -53.49% |
| Return on Assets (Trailing 12 Months) | -22.07% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.35 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.35 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 105.21M |
| Free Float | 96.38M |
| Market Capitalization | $169.39M |
| Average Volume (Last 20 Days) | 0.64M |
| Beta (Past 60 Months) | 0.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 32.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |